T1	AdverseReaction 412 434	cardiovascular effects
T2	Severity 400 411	significant
T4	AdverseReaction 446 451	fatal
T6	Severity 555 571	Life-threatening
T7	AdverseReaction 572 596	paradoxical bronchospasm
T8	Factor 597 600	can
T9	AdverseReaction 1027 1032	death
T12	AdverseReaction 1400 1406	deaths
T14	AdverseReaction 1601 1606	death
T15	Factor 1578 1582	risk
T17	AdverseReaction 2109 2114	death
T20	AdverseReaction 4790 4816	hypersensitivity reactions
T21	Factor 4817 4820	may
T22	AdverseReaction 5231 5255	paradoxical bronchospasm
T23	Factor 5219 5222	may
T24	Severity 5268 5284	life-threatening
T25	AdverseReaction 5535 5556	cardiovascular effect
T26	Severity 5523 5534	significant
T27	AdverseReaction 5589 5612	increases in pulse rate
T28	AdverseReaction 5589 5601;5614 5622;5636 5650	increases in systolic blood pressure
T29	AdverseReaction 5589 5601;5626 5650	increases in diastolic blood pressure
T31	AdverseReaction 5791 5802	ECG changes
T32	AdverseReaction 5812 5836	flattening of the T wave
T33	AdverseReaction 5838 5870	prolongation of the QTc interval
T34	AdverseReaction 5876 5897	ST segment depression
T35	AdverseReaction 6526 6566	aggravate pre-existing diabetes mellitus
T36	AdverseReaction 6526 6535;6571 6583	aggravate ketoacidosis
T37	AdverseReaction 6686 6697	hypokalemia
T39	Severity 6674 6685	significant
T40	AdverseReaction 6792 6822	adverse cardiovascular effects
T41	AdverseReaction 6866 6893	decrease in serum potassium
T42	AdverseReaction 7013 7040	increases in plasma glucose
T44	AdverseReaction 7097 7121	changes in blood glucose
T45	AdverseReaction 7065 7093	decreases in serum potassium
T47	DrugClass 370 374	LABA
T48	DrugClass 945 986	long-acting beta  2  -adrenergic agonists
T49	DrugClass 1255 1295	long-acting beta  2  -adrenergic agonist
T10	Factor 5498 5501	can
T18	DrugClass 5747 5760	beta-agonists
T19	DrugClass 6446 6459	beta2-agonist
T30	DrugClass 6636 6649	Beta2-agonist
T50	DrugClass 6975 7000	beta2-adrenergic agonists
T46	AdverseReaction 477 503	hypersensitivity reactions
T51	Factor 504 507	may
E1	AdverseReaction:T1 Effect:E2 Hypothetical2:E47
E2	Severity:T2
E4	AdverseReaction:T4 Hypothetical2:E47
E6	Severity:T6
E7	AdverseReaction:T7 Hypothetical:E8 Effect:E6
E8	Factor:T8
E9	AdverseReaction:T9 Hypothetical2:E48
E12	AdverseReaction:T12 Hypothetical:E49
E14	AdverseReaction:T14 Hypothetical:E15
E15	Factor:T15
E17	AdverseReaction:T17
E20	AdverseReaction:T20 Hypothetical:E21
E21	Factor:T21
E22	AdverseReaction:T22 Hypothetical:E23 Effect:E24
E23	Factor:T23
E24	Severity:T24
E25	AdverseReaction:T25 Effect:E26 Hypothetical:E10
E26	Severity:T26
E27	AdverseReaction:T27 Hypothetical:E10
E28	AdverseReaction:T28 Hypothetical:E10
E29	AdverseReaction:T29 Hypothetical:E10
E31	AdverseReaction:T31 Hypothetical:E18
E32	AdverseReaction:T32 Hypothetical:E18
E33	AdverseReaction:T33 Hypothetical:E18
E34	AdverseReaction:T34 Hypothetical:E18
E35	AdverseReaction:T35 Hypothetical:E19
E36	AdverseReaction:T36 Hypothetical:E19
E37	AdverseReaction:T37 Effect:E39 Hypothetical2:E30
E39	Severity:T39
E40	AdverseReaction:T40 Hypothetical:E30
E41	AdverseReaction:T41
E42	AdverseReaction:T42 Hypothetical2:E50
E44	AdverseReaction:T44
E45	AdverseReaction:T45
E47	DrugClass:T47
E48	DrugClass:T48
E49	DrugClass:T49
E10	Factor:T10
E18	DrugClass:T18
E19	DrugClass:T19
E30	DrugClass:T30
E50	DrugClass:T50
E46	AdverseReaction:T46 Hypothetical:E51
E51	Factor:T51
A1	CUI E1 C0476270
A2	UMLS-Preferred-Name E1 Cardiovascular symptoms
A3	MEDDRA-PT E1 Cardiovascular symptom
A4	MEDDRA-PT-ID E1 10075534
A5	CUI E4 C1306577
A6	UMLS-Preferred-Name E4 Death (finding)
A7	MEDDRA-PT E4 Death
A8	MEDDRA-PT-ID E4 10011906
A9	CUI E7 C0236072
A10	UMLS-Preferred-Name E7 Paradoxical bronchospasm
A11	MEDDRA-PT E7 Bronchospasm paradoxical
A12	MEDDRA-PT-ID E7 10006486
A13	LLT E7 Paradoxical bronchospasm
A14	LLT-ID E7 10033770
A15	CUI E9 C1306577
A16	UMLS-Preferred-Name E9 Death (finding)
A17	MEDDRA-PT E9 Death
A18	MEDDRA-PT-ID E9 10011906
A19	CUI E12 C1306577
A20	UMLS-Preferred-Name E12 Death (finding)
A21	MEDDRA-PT E12 Death
A22	MEDDRA-PT-ID E12 10011906
A23	CUI E14 C1306577
A24	UMLS-Preferred-Name E14 Death (finding)
A25	MEDDRA-PT E14 Death
A26	MEDDRA-PT-ID E14 10011906
A27	CUI E17 C1306577
A28	UMLS-Preferred-Name E17 Death (finding)
A29	MEDDRA-PT E17 Death
A30	MEDDRA-PT-ID E17 10011906
A31	CUI E20 C0020517
A32	UMLS-Preferred-Name E20 Hypersensitivity
A33	MEDDRA-PT E20 Hypersensitivity
A34	MEDDRA-PT-ID E20 10020751
A35	LLT E20 Hypersensitivity reaction
A36	LLT-ID E20 10020756
A37	CUI E22 C0236072
A38	UMLS-Preferred-Name E22 Paradoxical bronchospasm
A39	MEDDRA-PT E22 Bronchospasm paradoxical
A40	MEDDRA-PT-ID E22 10006486
A41	LLT E22 Paradoxical bronchospasm
A42	LLT-ID E22 10033770
A43	CUI E25 C0476270
A44	UMLS-Preferred-Name E25 Cardiovascular symptoms
A45	MEDDRA-PT E25 Cardiovascular symptom
A46	MEDDRA-PT-ID E25 10075534
A47	CUI E27 C0039231
A48	UMLS-Preferred-Name E27 Tachycardia
A49	MEDDRA-PT E27 Heart rate increased
A50	MEDDRA-PT-ID E27 10019303
A51	LLT E27 Pulse rate increased
A52	LLT-ID E27 10037490
A53	CUI E28 C0277884
A54	UMLS-Preferred-Name E28 Increased systolic arterial pressure
A55	MEDDRA-PT E28 Blood pressure systolic increased
A56	MEDDRA-PT-ID E28 10005760
A57	CUI E29 C0277889
A58	UMLS-Preferred-Name E29 Increased diastolic arterial pressure
A59	MEDDRA-PT E29 Blood pressure diastolic increased
A60	MEDDRA-PT-ID E29 10005739
A61	CUI E31 C0855329
A62	UMLS-Preferred-Name E31 Electrocardiographic changes
A63	MEDDRA-PT E31 Electrocardiogram change
A64	MEDDRA-PT-ID E31 10061116
A65	LLT E31 Change in ECG
A66	LLT-ID E31 10008396
A67	CUI E32 C0429059
A68	UMLS-Preferred-Name E32 Flattened T wave (finding)
A69	MEDDRA-PT E32 Electrocardiogram T wave amplitude decreased
A70	MEDDRA-PT-ID E32 10014394
A71	LLT E32 T wave flattening of
A72	LLT-ID E32 10042965
A73	CUI E33 C0855333
A74	UMLS-Preferred-Name E33 Electrocardiogram QT corrected interval prolonged
A75	MEDDRA-PT E33 Electrocardiogram QT prolonged
A76	MEDDRA-PT-ID E33 10014387
A77	LLT E33 Electrocardiogram QTc interval prolonged
A78	LLT-ID E33 10053698
A79	CUI E34 C0520887
A80	UMLS-Preferred-Name E34 ST segment depression (finding)
A81	MEDDRA-PT E34 Electrocardiogram ST segment depression
A82	MEDDRA-PT-ID E34 10014391
A83	LLT E34 ST segment depression
A84	LLT-ID E34 10041892
A85	CUI E35 C0235398
A86	UMLS-Preferred-Name E35 Diabetes mellitus exacerbated
A87	MEDDRA-PT E35 Diabetes mellitus
A88	MEDDRA-PT-ID E35 10012601
A89	LLT E35 Diabetes mellitus aggravated
A90	LLT-ID E35 10012603
A91	CUI E36 C0220982
A92	UMLS-Preferred-Name E36 Ketoacidosis
A93	MEDDRA-PT E36 Ketoacidosis
A94	MEDDRA-PT-ID E36 10023379
A95	CUI E37 C0020621
A96	UMLS-Preferred-Name E37 Hypokalemia
A97	MEDDRA-PT E37 Hypokalaemia
A98	MEDDRA-PT-ID E37 10021015
A99	LLT E37 Hypokalemia
A100	LLT-ID E37 10021018
A101	CUI E40 C0476270
A102	UMLS-Preferred-Name E40 Cardiovascular symptoms
A103	MEDDRA-PT E40 Cardiovascular symptom
A104	MEDDRA-PT-ID E40 10075534
A105	CUI E41 C0595885
A106	UMLS-Preferred-Name E41 Serum potassium decreased
A107	MEDDRA-PT E41 Blood potassium decreased
A108	MEDDRA-PT-ID E41 10005724
A109	LLT E41 Serum potassium decreased
A110	LLT-ID E41 10040378
A111	CUI E42 C0595877
A112	UMLS-Preferred-Name E42 Blood glucose increased
A113	MEDDRA-PT E42 Blood glucose increased
A114	MEDDRA-PT-ID E42 10005557
A115	CUI E44 C0877314
A116	UMLS-Preferred-Name E44 Blood glucose fluctuation
A117	MEDDRA-PT E44 Blood glucose fluctuation
A118	MEDDRA-PT-ID E44 10049803
A119	CUI E45 C0595885
A120	UMLS-Preferred-Name E45 Serum potassium decreased
A121	MEDDRA-PT E45 Blood potassium decreased
A122	MEDDRA-PT-ID E45 10005724
A123	LLT E45 Serum potassium decreased
A124	LLT-ID E45 10040378
A125	CUI E46 C0020517
A126	UMLS-Preferred-Name E46 Hypersensitivity
A127	MEDDRA-PT E46 Hypersensitivity
A128	MEDDRA-PT-ID E46 10020751
A129	LLT E46 Hypersensitivity reaction
A130	LLT-ID E46 10020756
